Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074410 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
A Phase 2 study, sponsored by Omeros Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02074410: Clinical Trial Phase 2 study, sponsored by Omeros Corporation.
NCT02074410 is a Phase 2 study that was terminated before completion, run by Omeros Corporation. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02074410, a Phase 2 study, was terminated before completion, sponsored by Omeros Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
Primary Outcome
Safety as assessed by adverse events
Interventions
- DRUG Placebo
- DRUG OMS643762
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-10-15 |
| Phase | Phase 2 |
Why NCT02074410 stopped before completion
NCT02074410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02074410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02074410 about?
NCT02074410 is a clinical study titled "Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease". The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
What is the current status of trial NCT02074410?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-01. Estimated completion is 2014-10-15.
What interventions are being tested in trial NCT02074410?
The interventions under investigation include: Placebo (DRUG), OMS643762 (DRUG).
Who is sponsoring clinical trial NCT02074410?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02074410's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia